Header Logo

Connection

Shabir Madhi to Respiratory Syncytial Virus, Human

Back to Details
This is a "connection" page, showing publications Shabir Madhi has written about Respiratory Syncytial Virus, Human.
Shabir Madhi
Connection Strength
8,709
Respiratory Syncytial Virus, Human
  1. A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants. J Infect Dis. 2025 Mar 17; 231(3):e478-e487.
    View in: PubMed
    Score: 0,840
  2. All-cause and pathogen-specific lower respiratory tract infection hospital admissions in children younger than 5 years during the COVID-19 pandemic (2020-22) compared with the pre-pandemic period (2015-19) in South Africa: an observational study. Lancet Infect Dis. 2023 09; 23(9):1031-1041.
    View in: PubMed
    Score: 0,738
  3. Pulmonary sequelae in 2-year-old children after hospitalisation for respiratory syncytial virus lower respiratory tract infection during infancy: an observational study. BMJ Open Respir Res. 2023 05; 10(1).
    View in: PubMed
    Score: 0,738
  4. Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus. BioDrugs. 2023 May; 37(3):295-309.
    View in: PubMed
    Score: 0,737
  5. Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants. N Engl J Med. 2020 07 30; 383(5):426-439.
    View in: PubMed
    Score: 0,609
  6. Impaired Transplacental Transfer of Respiratory Syncytial Virus-neutralizing Antibodies in Human Immunodeficiency Virus-infected Versus -uninfected Pregnant Women. Clin Infect Dis. 2019 06 18; 69(1):151-154.
    View in: PubMed
    Score: 0,564
  7. The bronchiolitis season is upon us--recommendations for the management and prevention of acute viral bronchiolitis. S Afr Med J. 2015 Sep 21; 105(7):525-6.
    View in: PubMed
    Score: 0,435
  8. Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine. Obstet Gynecol. 2025 Feb 01; 145(2):147-156.
    View in: PubMed
    Score: 0,207
  9. Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial. Obstet Gynecol. 2025 Feb 01; 145(2):157-167.
    View in: PubMed
    Score: 0,207
  10. Risk factors for severe respiratory syncytial virus-associated respiratory tract infection in a high HIV prevalence setting, South Africa, 2012 - 2018. BMC Infect Dis. 2024 Oct 09; 24(1):1128.
    View in: PubMed
    Score: 0,204
  11. Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY). Vaccine. 2024 Oct 24; 42(24):126276.
    View in: PubMed
    Score: 0,202
  12. Importance of nosocomial respiratory syncytial virus infections in an African setting. Trop Med Int Health. 2004 Apr; 9(4):491-8.
    View in: PubMed
    Score: 0,197
  13. Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season. J Pediatric Infect Dis Soc. 2024 Feb 26; 13(2):144-147.
    View in: PubMed
    Score: 0,195
  14. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial. J Infect Dis. 2023 08 11; 228(3):299-310.
    View in: PubMed
    Score: 0,188
  15. Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials. Nat Commun. 2023 07 19; 14(1):4347.
    View in: PubMed
    Score: 0,187
  16. Evaluation of Clinical Case Definitions for Respiratory Syncytial Virus Lower Respiratory Tract Infection in Young Children. J Pediatric Infect Dis Soc. 2023 May 31; 12(5):273-281.
    View in: PubMed
    Score: 0,185
  17. The attributable fraction of respiratory syncytial virus among patients of different ages with influenza-like illness and severe acute respiratory illness in a high HIV prevalence setting, South Africa, 2012-2016. Int J Infect Dis. 2023 Sep; 134:71-77.
    View in: PubMed
    Score: 0,185
  18. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023 03; 7(3):180-189.
    View in: PubMed
    Score: 0,181
  19. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022 05 28; 399(10340):2047-2064.
    View in: PubMed
    Score: 0,173
  20. Global Respiratory Syncytial Virus-Related Infant Community Deaths. Clin Infect Dis. 2021 09 02; 73(Suppl_3):S229-S237.
    View in: PubMed
    Score: 0,164
  21. Deaths Attributed to Respiratory Syncytial Virus in Young Children in High-Mortality Rate Settings: Report from Child Health and Mortality Prevention Surveillance (CHAMPS). Clin Infect Dis. 2021 09 02; 73(Suppl_3):S218-S228.
    View in: PubMed
    Score: 0,164
  22. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 07 30; 383(5):415-425.
    View in: PubMed
    Score: 0,152
  23. Placental Transfer of Respiratory Syncytial Virus Antibody Among HIV-Exposed, Uninfected Infants. J Pediatric Infect Dis Soc. 2020 Jul 13; 9(3):349-356.
    View in: PubMed
    Score: 0,152
  24. Characterization of human respiratory syncytial virus (RSV) isolated from HIV-exposed-uninfected and HIV-unexposed infants in South Africa during 2015-2017. Influenza Other Respir Viruses. 2020 07; 14(4):403-411.
    View in: PubMed
    Score: 0,148
  25. The Impact of Human Immunodeficiency Virus Exposure on Respiratory Syncytial Virus-associated Severe Respiratory Illness in South African Infants, 2011-2016. Clin Infect Dis. 2019 11 27; 69(12):2208-2211.
    View in: PubMed
    Score: 0,145
  26. Performance of Surveillance Case Definitions in Detecting Respiratory Syncytial Virus Infection Among Young Children Hospitalized With Severe Respiratory Illness-South Africa, 2009-2014. J Pediatric Infect Dis Soc. 2019 Sep 25; 8(4):325-333.
    View in: PubMed
    Score: 0,144
  27. Burden of Respiratory Syncytial Virus Infection in South African Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Pregnant and Postpartum Women: A Longitudinal Cohort Study. Clin Infect Dis. 2018 05 17; 66(11):1658-1665.
    View in: PubMed
    Score: 0,131
  28. Epidemiology of respiratory syncytial virus-associated acute lower respiratory tract infection hospitalizations among HIV-infected and HIV-uninfected South African children, 2010-2011. J Infect Dis. 2013 Dec 15; 208 Suppl 3:S217-26.
    View in: PubMed
    Score: 0,096
  29. Replacement and positive evolution of subtype A and B respiratory syncytial virus G-protein genotypes from 1997-2012 in South Africa. J Infect Dis. 2013 Dec 15; 208 Suppl 3:S227-37.
    View in: PubMed
    Score: 0,096
  30. Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children. J Clin Virol. 2006 Jul; 36(3):215-21.
    View in: PubMed
    Score: 0,057
  31. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis. 2006 Feb 15; 193(4):573-81.
    View in: PubMed
    Score: 0,056
  32. Epidemiology of human metapneumovirus among children with severe or very severe pneumonia in high pneumonia burden settings: the Pneumonia Etiology Research for Child Health (PERCH) study experience. Clin Microbiol Infect. 2025 Mar; 31(3):441-450.
    View in: PubMed
    Score: 0,051
  33. Impact of Respiratory Syncytial Virus and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection on Clinical Severity and Outcomes Among Children Hospitalized With Lower Respiratory Tract Infections in Soweto, South Africa. Pediatr Infect Dis J. 2025 Feb 01; 44(2):107-111.
    View in: PubMed
    Score: 0,051
  34. Genetic diversity and molecular epidemiology of respiratory syncytial virus over four consecutive seasons in South Africa: identification of new subgroup A and B genotypes. J Gen Virol. 2001 Sep; 82(Pt 9):2117-2124.
    View in: PubMed
    Score: 0,041
  35. Respiratory syncytial virus in adults with severe acute respiratory illness in a high HIV prevalence setting. J Infect. 2017 10; 75(4):346-355.
    View in: PubMed
    Score: 0,031
  36. Association of C-Reactive Protein With Bacterial and Respiratory Syncytial Virus-Associated Pneumonia Among Children Aged <5 Years in the PERCH Study. Clin Infect Dis. 2017 Jun 15; 64(suppl_3):S378-S386.
    View in: PubMed
    Score: 0,031
  37. Deaths associated with respiratory syncytial and influenza viruses among persons =5 years of age in HIV-prevalent area, South Africa, 1998-2009(1). Emerg Infect Dis. 2015 Apr; 21(4):600-8.
    View in: PubMed
    Score: 0,026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.